Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine CR for MDD in IBS Patients
NCT01916200Phase 4Withdrawn
- Sponsor
- GSK
- Start
- Jan 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of paroxetine in major depressive disorder (MDD) (2 arms), sponsored by GSK. Primary endpoint: Hamilton Depression Rating Scale 17 items at 8 weeks. Planned start Jan 2014; status: withdrawn.
02
Drugs
paroxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01916200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01916200.